BANGALORE, India and BRIDGEWATER, New Jersey, April 2, 2013 /PRNewswire/ --
Aurigene will be presenting poster sessions for three of its programs at the American Associate of Cancer Research (April 6-10 in Washington, DC).
PD-1 is a 29-amino acid novel peptide (NP-12) that displays sub-nM potency in disruption of PD1-PDL1/L2 interactions. NP-12 is highly effective in antagonizing PD1 signalling, with desirable in vivo exposure upon s.c. dosing. NP-12 inhibits tumor growth and metastasis in preclinical models of cancer and is well tolerated with no overt toxicity at any of the tested doses; currently in IND studies.
Session Title: Equipotent antagonism, transient immune activation and excellent antitumor efficacy with a peptide inhibitor of PD-1 immune check point pathway
ID: Cytokines, Modification of the Tumor Microenvironment, and Intervention - 1231/11 PO.IM02.02.
Date and Time: Mon, Apr 8, 1:00 - 5:00 PM
Bet Bromodomain: Aurigene has identified novel chemical series of lead compounds that show excellent cell based activity. Demonstration of efficacy is on-going.
Session Title: Identification of potent BET bromodomain inhibitors for treatment of cancer
ID: Epigenetic Therapy and Risk Biomarkers 671/1 - PO.MCB06.05.
Date and Time: Sun, Apr 7, 1:00 - 5:00 PM
NAMPT: Aurigene has identified novel chemical series of compounds - lead compounds show excellent cell based activity correlating with biochemical potency, favorable ADME profile, excellent pharmacokinetic profile in mice with good oral bioavailability. The lead compound shows excellent efficacy with tumor regression in pancreatic cancer xenograft mice models. Preclinical studies on-going.
Session Title: Novel inhibitors of nicotinamide phos
Copyright©2012 PR Newswire.
All rights reserved